Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PERMINDER J S BHATIA

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1013002328
CMS profile
45675
Location
FRESNO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$77,400.96

303 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 4 of 7; records 151–200 of 303 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PERMINDER J S BHATIA

NPI 1013002328 · CMS profile ID 45675

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

FRESNO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 7; records 151–200 of 303 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1013002328?year=2024&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PERMINDER J S BHATIA, NPI 1013002328, CMS profile ID 45675. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 7; records 151–200 of 303 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1013002328?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). PERMINDER J S BHATIA, NPI 1013002328, CMS profile ID 45675. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 7; records 151–200 of 303 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1013002328?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
PERMINDER J S BHATIA, NPI 1013002328, CMS profile ID 45675, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 7; records 151–200 of 303 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1013002328?year=2024&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

303 matching records · $77,400.96 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 303 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 303.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
UCB, Inc. $38.1806/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143116205 CMS
ANI Pharmaceuticals, Inc. $19.9806/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091167704 CMS
Genentech USA, Inc. $18.1706/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133087521 CMS
CATALYST PHARMACEUTICALS, INC. $26.6806/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144449370 CMS
Neurelis, Inc. $23.8506/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145634556 CMS
Eisai Inc. $72.8106/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110772673 CMS
Eisai Inc. $1,755.0006/13/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110772709 CMS
Novartis Pharmaceuticals Corporation $13.8606/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086690745 CMS
UCB, Inc. $1.9506/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143116201 CMS
UCB, Inc. $20.2506/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143116203 CMS
Azurity Pharmaceuticals, Inc. $20.7906/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134003339 CMS
Lundbeck LLC $26.8706/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145897516 CMS
UCB, Inc. $13.1606/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143116199 CMS
Alexion Pharmaceuticals, Inc. $19.5806/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093888384 CMS
HARMONY BIOSCIENCES LLC $64.9906/10/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126058225 CMS
GE HEALTHCARE $20.9506/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144685690 CMS
HARMONY BIOSCIENCES LLC $17.6806/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126058229 CMS
Teva Pharmaceuticals USA, Inc. $165.0006/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151490475 CMS
ABBVIE INC. $28.8306/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103322116 CMS
MDD US Operations, LLC $21.6306/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147770286 CMS
Neurocrine Biosciences, Inc. $24.4406/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150841676 CMS
SK Life Science, Inc. $6.8605/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154111333 CMS
ABBVIE INC. $6.4005/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103322114 CMS
ABBVIE INC. $18.2505/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103322112 CMS
Amneal Pharmaceuticals LLC $19.1305/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139180577 CMS
Neurelis, Inc. $22.0005/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145634552 CMS
ANI Pharmaceuticals, Inc. $18.4505/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091167388 CMS
Octapharma USA, Inc. $13.0005/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142312757 CMS
Otsuka America Pharmaceutical, Inc. $6,102.0005/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118862411 CMS
EMD Serono, Inc. $32.5105/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120248887 CMS
Biogen, Inc. $24.8505/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104855554 CMS
NEUROPACE, INC. $20.7505/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153275474 CMS
UCB, Inc. $31.6005/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143116197 CMS
Alexion Pharmaceuticals, Inc. $19.3205/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1094012529 CMS
Ipsen Biopharmaceuticals, Inc $23.1905/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091959593 CMS
Teva Pharmaceuticals USA, Inc. $29.3105/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151490399 CMS
Neurocrine Biosciences, Inc. $4.7905/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150888497 CMS
ABBVIE INC. $8.2105/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103322110 CMS
Neurocrine Biosciences, Inc. $18.8305/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150862825 CMS
Otsuka America Pharmaceutical, Inc. $435.0005/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118862409 CMS
Eisai Inc. $7,780.0005/07/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110772707 CMS
Novartis Pharmaceuticals Corporation $15.9705/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086690743 CMS
PFIZER INC. $15.2005/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131505185 CMS
Genentech USA, Inc. $25.5705/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133087533 CMS
SK Life Science, Inc. $18.3805/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154111327 CMS
ABBVIE INC. $3.6305/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103322108 CMS
HARMONY BIOSCIENCES LLC $26.4305/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126058227 CMS
HARMONY BIOSCIENCES LLC $1.4805/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126058239 CMS
Lilly USA, LLC $21.7905/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135280652 CMS
Teva Pharmaceuticals USA, Inc. $125.0005/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151490381 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $17,503.29 211
PY2020 $28,198.74 222
PY2021 $21,332.91 314
PY2022 $22,569.40 284
PY2023 $29,586.01 272
PY2024 $77,400.96 303
PY2025 $82,629.13 327

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,405.53 6
PY2025 Principal investigator $1,597,612.15 218
PY2024 Recipient $1,621.97 3
PY2024 Principal investigator $1,125,524.72 121
PY2023 Recipient $465.64 2
PY2023 Principal investigator $1,137,330.81 86
PY2022 Recipient $3,881.00 3
PY2022 Principal investigator $1,670,191.56 73
PY2021 Recipient $444.81 1
PY2021 Principal investigator $885,391.87 74
PY2020 Principal investigator $653,742.50 69
PY2019 Principal investigator $906,341.06 121

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

224 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,242.56 12/31/2025 Covered Recipient Teaching Hospital
EMORY UNIVERSITY HOSPITAL
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Upper Limb Essential Tremor No dispute reported 06/30/2026 1202411598
Principal investigator 1 ABBVIE INC. $1,854.00 12/31/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER
A Phase 3 Multicenter 24-Week Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of Chronic Migraine No dispute reported 06/30/2026 1202533953
Principal investigator 1 ABBVIE INC. $962.76 12/31/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER
A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age No dispute reported 06/30/2026 1202533955
Principal investigator 1 ABBVIE INC. $582.00 12/31/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER
A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Atogepant in Pediatric Subjects 6 to 17 years of age with Migraine No dispute reported 06/30/2026 1202533957
Principal investigator 1 ABBVIE INC. $1,440.00 12/31/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202533959
Principal investigator 1 ABBVIE INC. $828.36 12/31/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER
An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of ABBV-951 in Subjects With Advanced Parkinson s Disease No dispute reported 06/30/2026 1202533961
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension No dispute reported 06/30/2026 1202535381
Principal investigator 1 SK Life Science, Inc. $850.00 12/24/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER INC.
YKP3089C025 No dispute reported 06/30/2026 1252274877
Principal investigator 1 SK Life Science, Inc. $1,000.00 12/24/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER INC.
YKP3089C025 No dispute reported 06/30/2026 1252274879
Principal investigator 1 Ipsen Innovation $7,500.00 12/19/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287682
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $241.00 12/17/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045208
Principal investigator 1 ABBVIE INC. $1,224.60 12/04/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202529024
Principal investigator 1 ABBVIE INC. $1,837.35 12/04/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202529026
Principal investigator 1 H. Lundbeck A S $2,380.00 12/01/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251777903
Principal investigator 1 H. Lundbeck A S $2,006.00 12/01/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251777907
Principal investigator 1 H. Lundbeck A S $1,902.00 12/01/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251777912
Principal investigator 1 Ipsen Innovation $689.20 12/01/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287684
Principal investigator 1 Ipsen Innovation $689.20 12/01/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287686
Principal investigator 1 Ipsen Pharma SAS $750.00 11/24/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303397
Principal investigator 1 Ipsen Innovation $1,721.33 11/19/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287680
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $638.00 11/19/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045202
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $241.00 11/19/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045204
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $838.00 11/19/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045206
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $241.00 11/19/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045358
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $838.00 11/19/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045360
Principal investigator 1 ABBVIE INC. $1,820.00 11/13/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202524099
Principal investigator 1 ABBVIE INC. $693.00 11/13/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202524101
Principal investigator 1 ABBVIE INC. $612.30 11/05/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202522053
Principal investigator 1 Ipsen Innovation $1,757.21 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287638
Principal investigator 1 Ipsen Innovation $1,757.21 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287640
Principal investigator 1 Ipsen Innovation $2,060.21 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287642
Principal investigator 1 Ipsen Innovation $2,918.50 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287644
Principal investigator 1 Ipsen Innovation $2,918.50 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287646
Principal investigator 1 Ipsen Innovation $2,918.50 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287648
Principal investigator 1 Ipsen Innovation $2,918.50 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287650
Principal investigator 1 Ipsen Innovation $689.20 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287652
Principal investigator 1 Ipsen Innovation $689.20 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287654
Principal investigator 1 Ipsen Innovation $689.20 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287656
Principal investigator 1 Ipsen Innovation $689.20 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287658
Principal investigator 1 Ipsen Innovation $1,565.53 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287660
Principal investigator 1 Ipsen Innovation $1,687.96 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287662
Principal investigator 1 Ipsen Innovation $1,757.21 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287664
Principal investigator 1 Ipsen Innovation $689.20 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287666
Principal investigator 1 Ipsen Innovation $2,918.50 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287668
Principal investigator 1 Ipsen Innovation $2,084.33 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287670
Principal investigator 1 Ipsen Innovation $2,439.64 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287672
Principal investigator 1 Ipsen Innovation $689.20 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287674
Principal investigator 1 Ipsen Innovation $689.20 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287676
Principal investigator 1 Ipsen Innovation $2,918.50 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287678
Principal investigator 1 H. Lundbeck A S $327.00 10/15/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251775693
Principal investigator 1 SK Life Science, Inc. $1,678.25 10/15/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER INC.
YKP3089C049 No dispute reported 06/30/2026 1252274845
Principal investigator 1 ABBVIE INC. $15,370.31 10/14/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202516739
Principal investigator 1 ABBVIE INC. $3,105.70 10/09/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202515399
Principal investigator 1 ABBVIE INC. $813.70 10/09/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202516171
Principal investigator 1 ABBVIE INC. $284.85 10/09/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202516173
Principal investigator 1 ABBVIE INC. $236.93 10/09/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202516467
Principal investigator 1 H. Lundbeck A S $7,793.00 10/08/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251775490
Principal investigator 1 Ipsen Innovation $689.20 09/29/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287636
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $632.00 09/24/2025 Non-covered Recipient Entity
THE CENTER FOR CLINICAL RESEARCH LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067693
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $2,147.60 09/24/2025 Non-covered Recipient Entity
THE CENTER FOR CLINICAL RESEARCH LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067695
Principal investigator 1 Roche Products Limited $91.80 09/24/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628093
Principal investigator 1 H. Lundbeck A S $2,380.00 09/10/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251774444
Principal investigator 1 H. Lundbeck A S $1,902.00 09/10/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251774449
Principal investigator 1 H. Lundbeck A S $327.00 09/10/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251774454
Principal investigator 1 ABBVIE INC. $1,837.35 09/04/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202508728
Principal investigator 1 Ipsen Innovation $126.00 08/19/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287634
Principal investigator 1 ABBVIE INC. $3,939.04 08/13/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202504471
Principal investigator 1 ABBVIE INC. $2,501.55 08/05/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202501800
Principal investigator 1 ABBVIE INC. $1,000.00 07/30/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202500472
Principal investigator 1 ABBVIE INC. $560.00 07/30/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202500474
Principal investigator 1 ABBVIE INC. $75.00 07/30/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202500476
Principal investigator 1 Ipsen Innovation $689.20 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287600
Principal investigator 1 Ipsen Innovation $689.20 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287602
Principal investigator 1 Ipsen Innovation $1,757.21 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287604
Principal investigator 1 Ipsen Innovation $689.20 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287606
Principal investigator 1 Ipsen Innovation $689.20 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287608
Principal investigator 1 Ipsen Innovation $1,910.93 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287610
Principal investigator 1 Ipsen Innovation $689.20 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287612
Principal investigator 1 Ipsen Innovation $1,687.96 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287614
Principal investigator 1 Ipsen Innovation $2,060.21 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287616
Principal investigator 1 Ipsen Innovation $689.20 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287618
Principal investigator 1 Ipsen Innovation $1,910.93 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287620
Principal investigator 1 Ipsen Innovation $689.20 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287622
Principal investigator 1 Ipsen Innovation $689.20 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287624
Principal investigator 1 Ipsen Innovation $1,687.96 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287626
Principal investigator 1 Ipsen Innovation $2,060.21 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287628
Principal investigator 1 Ipsen Innovation $689.20 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287630
Principal investigator 1 Ipsen Innovation $1,910.93 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287632
Principal investigator 1 ABBVIE INC. $75.00 07/18/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202498930
Principal investigator 1 SK Life Science, Inc. $2,387.00 07/16/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER INC.
YKP3089C049 No dispute reported 06/30/2026 1252274835
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,000.00 07/14/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045200
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $241.00 07/11/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045198
Principal investigator 1 ABBVIE INC. $791.10 07/02/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202495047
Principal investigator 1 ABBVIE INC. $1,000.00 07/02/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202495855
Principal investigator 1 ABBVIE INC. $1,888.90 07/02/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202495857
Principal investigator 1 Ipsen Pharma SAS $1,699.65 06/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303387
Principal investigator 1 Ipsen Pharma SAS $1,699.65 06/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303389
Principal investigator 1 Ipsen Pharma SAS $1,699.65 06/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303391
Principal investigator 1 Ipsen Pharma SAS $1,699.65 06/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303393
Principal investigator 1 Ipsen Pharma SAS $1,699.65 06/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303395
Principal investigator 1 ABBVIE INC. $13,664.00 06/26/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202493169
Principal investigator 1 ABBVIE INC. $500.00 06/26/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202493183
Principal investigator 1 ABBVIE INC. $163.80 06/26/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202493185
Principal investigator 1 ABBVIE INC. $2,684.00 06/26/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202493187
Principal investigator 1 ABBVIE INC. $1,042.60 06/26/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202493189
Principal investigator 1 ABBVIE INC. $473.20 06/26/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202493191
Principal investigator 1 H. Lundbeck A S $2,000.00 06/26/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Cognitive interview study to evaluate phase 2 trial anchors in patients with Parkinsons Disease No dispute reported 06/30/2026 1251771661
Principal investigator 1 H. Lundbeck A S $3,300.00 06/26/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Cognitive interview study to evaluate phase 2 trial anchors in patients with Parkinsons Disease No dispute reported 06/30/2026 1251771665
Principal investigator 1 ABBVIE INC. $731.25 06/24/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202492791
Principal investigator 1 ABBVIE INC. $750.00 06/24/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202492793
Principal investigator 1 ABBVIE INC. $843.75 06/24/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202492795
Principal investigator 1 Roche Products Limited $306.00 06/24/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628084
Principal investigator 1 Roche Products Limited $306.00 06/24/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628089
Principal investigator 1 ABBVIE INC. $2,476.18 06/19/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202492445
Principal investigator 1 ABBVIE INC. $594.00 06/05/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202490587
Principal investigator 1 ABBVIE INC. $3,000.00 06/05/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202490591
Principal investigator 1 ABBVIE INC. $2,224.20 06/03/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202488051
Principal investigator 1 ABBVIE INC. $43,420.00 05/29/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202487089
Principal investigator 1 Alexion Pharmaceuticals, Inc. $208.00 05/22/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
Long Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies No dispute reported 06/30/2026 1185552095
Principal investigator 1 Ipsen Pharma SAS $1,000.00 05/19/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303381
Principal investigator 1 Ipsen Pharma SAS $750.00 05/19/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303383
Principal investigator 1 Ipsen Pharma SAS $1,500.00 05/19/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303385
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $638.00 05/14/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045194
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $241.00 05/14/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045196
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $638.00 05/14/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045346
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $638.00 05/14/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045348
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $638.00 05/14/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045350
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $638.00 05/14/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045352
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $638.00 05/14/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045354
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $638.00 05/14/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045356
Principal investigator 1 Eli Lilly and Company $14,230.00 05/13/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187887066
Principal investigator 1 ABBVIE INC. $3,817.95 05/07/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202483735
Principal investigator 1 ABBVIE INC. $12,802.00 05/07/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202484029
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $3,170.00 05/07/2025 Non-covered Recipient Entity
THE CENTER FOR CLINICAL RESEARCH LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066377
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,500.00 05/07/2025 Non-covered Recipient Entity
THE CENTER FOR CLINICAL RESEARCH LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066379
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $7,148.00 05/07/2025 Non-covered Recipient Entity
THE CENTER FOR CLINICAL RESEARCH LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066381
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,200.00 05/07/2025 Non-covered Recipient Entity
THE CENTER FOR CLINICAL RESEARCH LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066383
Principal investigator 1 ABBVIE INC. $1,960.20 05/06/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202482245
Principal investigator 1 ABBVIE INC. $1,977.75 05/06/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202482247
Principal investigator 1 Ipsen Innovation $2,984.04 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287556
Principal investigator 1 Ipsen Innovation $2,439.64 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287558
Principal investigator 1 Ipsen Innovation $1,687.96 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287560
Principal investigator 1 Ipsen Innovation $1,910.93 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287562
Principal investigator 1 Ipsen Innovation $1,565.53 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287564
Principal investigator 1 Ipsen Innovation $689.20 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287566
Principal investigator 1 Ipsen Innovation $2,559.60 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287568
Principal investigator 1 Ipsen Innovation $1,565.53 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287570
Principal investigator 1 Ipsen Innovation $2,439.64 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287572
Principal investigator 1 Ipsen Innovation $689.20 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287574
Principal investigator 1 Ipsen Innovation $2,060.21 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287576
Principal investigator 1 Ipsen Innovation $1,687.96 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287578
Principal investigator 1 Ipsen Innovation $1,565.53 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287580
Principal investigator 1 Ipsen Innovation $2,984.04 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287582
Principal investigator 1 Ipsen Innovation $2,060.21 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287584
Principal investigator 1 Ipsen Innovation $2,439.64 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287586
Principal investigator 1 Ipsen Innovation $2,984.04 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287588
Principal investigator 1 Ipsen Innovation $2,984.04 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287590
Principal investigator 1 Ipsen Innovation $1,565.53 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287592
Principal investigator 1 Ipsen Innovation $689.20 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287594
Principal investigator 1 Ipsen Innovation $689.20 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287596
Principal investigator 1 Ipsen Innovation $2,984.04 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287598
Principal investigator 1 ABBVIE INC. $2,500.00 04/24/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202479409
Principal investigator 1 SK Life Science, Inc. $1,491.85 04/23/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER INC.
YKP3089C049 No dispute reported 06/30/2026 1252274801
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $40,794.72 04/14/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER
A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1214124850
Principal investigator 1 ABBVIE INC. $8,564.50 04/10/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson s Disease With Motor Fluctuations (TEMPO-3) No dispute reported 06/30/2026 1202476103
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $2,141.30 04/04/2025 Non-covered Recipient Entity
Neuro Pain Medical Center Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068423
Principal investigator 1 ABBVIE INC. $2,883.40 04/03/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202473635
Principal investigator 1 ABBVIE INC. $1,221.15 04/03/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202473827
Principal investigator 1 ABBVIE INC. $2,188.55 04/03/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202473831
Principal investigator 1 ABBVIE INC. $2,612.25 04/03/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202473833
Principal investigator 1 Ipsen Pharma SAS $1,699.65 04/01/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303379
Principal investigator 1 Eli Lilly and Company $256,357.00 03/19/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187884890
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $638.00 03/14/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045192
Principal investigator 1 ABBVIE INC. $3,211.26 03/13/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202463814
Principal investigator 1 ABBVIE INC. $12,052.00 03/07/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
M23-712 - A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202461275
Principal investigator 1 ABBVIE INC. $6,325.65 03/07/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202461279
Principal investigator 1 ABBVIE INC. $1,750.32 03/06/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202458135
Principal investigator 1 ABBVIE INC. $17,917.93 03/06/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202459047
Principal investigator 1 H. Lundbeck A S $370.36 03/05/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251768236
Principal investigator 1 H. Lundbeck A S $238.89 03/05/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251768240
Principal investigator 1 H. Lundbeck A S $123.64 03/05/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251768244
Principal investigator 1 H. Lundbeck A S $26.05 03/05/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251768248
Principal investigator 1 H. Lundbeck A S $25.00 03/05/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251768252
Principal investigator 1 H. Lundbeck A S $126.60 03/05/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251768256
Principal investigator 1 H. Lundbeck A S $477.01 02/27/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251767940
Principal investigator 1 Eli Lilly and Company $2,049.50 02/25/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187887020
Principal investigator 1 ABBVIE INC. $150.00 02/06/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202447521
Principal investigator 1 ABBVIE INC. $1,273.78 02/05/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202444443
Principal investigator 1 ABBVIE INC. $573.30 02/05/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER
M20-098 - Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202446496
Principal investigator 1 ABBVIE INC. $3,291.30 02/05/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202446499
Principal investigator 1 UCB SA $27,104.95 02/05/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
A dose-blinded extension study to evaluate the long-term efficacy, safety, and tolerability of UCB0599 in study participants with Parkinsons disease No dispute reported 06/30/2026 1246657562
Principal investigator 1 Eli Lilly and Company $615.74 01/31/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) No dispute reported 06/30/2026 1187884892
Principal investigator 1 Eli Lilly and Company $570.00 01/31/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-FINDING STUDY EVALUATING LY3848575 IN CHRONIC NEUROPATHIC PAIN ASSOCIATED WITH DISTAL SENSORY POLYNEUROPATHY No dispute reported 06/30/2026 1187885654
Principal investigator 1 Eli Lilly and Company $2,720.35 01/31/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187886984
Principal investigator 1 Eli Lilly and Company $306.56 01/31/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 1187887064
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $11,896.85 01/31/2025 Non-covered Recipient Entity
Neuro Pain Medical Center Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066259
Principal investigator 1 Eli Lilly and Company $9,933.14 01/27/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187886204
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $638.00 01/22/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045188
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $241.00 01/22/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045190
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $638.00 01/22/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045342
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $638.00 01/22/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045344
Principal investigator 1 Eli Lilly and Company $218,226.00 01/21/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187884416
Principal investigator 1 Eli Lilly and Company $56,716.00 01/21/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 1187885290
Principal investigator 1 Eli Lilly and Company $132,434.00 01/21/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) No dispute reported 06/30/2026 1187887016
Recipient ACADIA Pharmaceuticals Inc $319.51 01/17/2025 Covered Recipient Physician ACP-204 No dispute reported 06/30/2026 1245932619
Recipient ACADIA Pharmaceuticals Inc $463.96 01/17/2025 Covered Recipient Physician ACP-204 No dispute reported 06/30/2026 1245932621
Recipient ACADIA Pharmaceuticals Inc $230.25 01/17/2025 Covered Recipient Physician ACP-204 No dispute reported 06/30/2026 1245932623
Recipient ACADIA Pharmaceuticals Inc $96.81 01/17/2025 Covered Recipient Physician ACP-204 No dispute reported 06/30/2026 1245932625
Recipient ACADIA Pharmaceuticals Inc $125.00 01/17/2025 Covered Recipient Physician ACP-204 No dispute reported 06/30/2026 1245932627
Recipient ACADIA Pharmaceuticals Inc $170.00 01/17/2025 Covered Recipient Physician ACP-204 No dispute reported 06/30/2026 1245932629
Principal investigator 1 UCB SA $18,220.00 01/17/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
A MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF UCB0022 IN STUDY PARTICIPANTS WITH ADVANCED Parkinsons DISEASE No dispute reported 06/30/2026 1246658720
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $190.00 01/14/2025 Non-covered Recipient Entity
Neuro Pain Medical Center Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066257
Principal investigator 1 Eli Lilly and Company $5.79 01/09/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187886202
Principal investigator 1 Roche Products Limited $306.00 01/09/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628063
Principal investigator 1 Roche Products Limited $306.00 01/09/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628069
Principal investigator 1 Roche Products Limited $306.00 01/09/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628073
Principal investigator 1 Roche Products Limited $306.00 01/09/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628078
Principal investigator 1 UCB SA $12,444.90 01/09/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
A PATIENT- AND INVESTIGATOR-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BEPRANEMAB (UCB0107) IN STUDY PARTICIPANTS WITH PRODROMAL TO MILD ALZHEIMERS DISEASE (AD), FOLLOWED BY AN OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1246659398
Principal investigator 1 UCB SA $57,973.45 01/08/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, 18-MONTH PHASE 2A STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORAL UCB0599 IN STUDY PARTICIPANTS WITH EARLY Parkinsons DISEASE No dispute reported 06/30/2026 1246657333
Principal investigator 1 Eli Lilly and Company $94,433.00 01/07/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187886564
Principal investigator 1 Eli Lilly and Company $114,224.00 01/07/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-FINDING STUDY EVALUATING LY3848575 IN CHRONIC NEUROPATHIC PAIN ASSOCIATED WITH DISTAL SENSORY POLYNEUROPATHY No dispute reported 06/30/2026 1187887018
Principal investigator 1 ABBVIE INC. $4,125.08 01/02/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202434083
Principal investigator 1 ABBVIE INC. $4,433.40 01/02/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202436304
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $116,355.16 01/01/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1214123704